Leading Pharmaceutical Innovation Trends and Drivers for Growth in the Pharmaceutical Industry / by Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz.

Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business pra...

Full description

Saved in:
Bibliographic Details
Main Authors: Gassmann, Oliver (Author), Reepmeyer, Gerrit (Author), von Zedtwitz, Maximilian (Author)
Corporate Author: SpringerLink (Online service)
Format: eBook
Language:English
Published: Berlin, Heidelberg : Springer Berlin Heidelberg : Imprint: Springer, 2008.
Edition:2nd ed. 2008.
Series:Springer eBook Collection.
Subjects:
Online Access:Click to view e-book
Holy Cross Note:Loaded electronically.
Electronic access restricted to members of the Holy Cross Community.

MARC

LEADER 00000nam a22000005i 4500
001 b3295620
003 MWH
005 20191024041030.0
007 cr nn 008mamaa
008 100301s2008 gw | s |||| 0|eng d
020 |a 9783540776369 
024 7 |a 10.1007/978-3-540-77636-9  |2 doi 
035 |a (DE-He213)978-3-540-77636-9 
050 4 |a E-Book 
072 7 |a KJMV6  |2 bicssc 
072 7 |a BUS087000  |2 bisacsh 
072 7 |a KJMV6  |2 thema 
072 7 |a PDG  |2 thema 
100 1 |a Gassmann, Oliver.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
245 1 0 |a Leading Pharmaceutical Innovation  |h [electronic resource] :  |b Trends and Drivers for Growth in the Pharmaceutical Industry /  |c by Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz. 
250 |a 2nd ed. 2008. 
264 1 |a Berlin, Heidelberg :  |b Springer Berlin Heidelberg :  |b Imprint: Springer,  |c 2008. 
300 |a XVI, 186 p. 47 illus.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Springer eBook Collection 
505 0 |a Innovation: Key to Success in the Pharmaceutical Industry -- The Industry Challenge: Do You Really Want to Be in This Business? -- The Science and Technology Challenge: How to Find New Drugs -- The Pipeline Management Challenge: How to Organize Innovation -- The Internationalization Challenge: Where to Get Access to Innovation -- Management Answers to Pharmaceutical R&D Challenges -- Future Directions and Trends. 
520 |a Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia. "One way we try to foster innovation - both the technological innovation and the organizational innovation - is to align our business objectives with our ideals." Dr. Daniel Vasella, CEO, Novartis International "Pharmaceutical innovation is in crisis. The industry will have to change both its innovation processes and its business models in order to reverse these trends and prosper in the future. Professors Gassmann, Reepmeyer and von Zedtwitz have marshalled together an impressive array of research in one volume. This book should prove to be an indispensable resource for all participants in the pharmaceutical industry." Prof. Henry Chesbrough, Executive Director, Center for Open Innovation, Haas School of Business, University of California, Berkeley "It́s time for a paradigm shift in pharmaceutical R&D. This book will tell you why." Dr. Goetz Baumann, Business Unit Manager, Hoffmann-La Roche (Germany) "This book offers a fact based, comprehensive insight to the increasing challenges of todaỳs drug development. Well worth reading not just for newcomers to the industry but also for industry professionals who want to understand the big picture". Dr. Pius Renner, Head of Strategic Planning and Portfolio Management in Development, Novartis Pharma . 
590 |a Loaded electronically. 
590 |a Electronic access restricted to members of the Holy Cross Community. 
650 0 |a Management. 
650 0 |a Industrial management. 
650 0 |a Economic policy. 
650 0 |a Public health. 
650 0 |a Pharmacy. 
690 |a Electronic resources (E-books) 
700 1 |a Reepmeyer, Gerrit.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
700 1 |a von Zedtwitz, Maximilian.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
830 0 |a Springer eBook Collection. 
856 4 0 |u https://holycross.idm.oclc.org/login?auth=cas&url=https://doi.org/10.1007/978-3-540-77636-9  |3 Click to view e-book 
907 |a .b32956204  |b 04-18-22  |c 02-26-20 
998 |a he  |b 02-26-20  |c m  |d @   |e -  |f eng  |g gw   |h 0  |i 1 
912 |a ZDB-2-SBE 
950 |a Business and Economics (Springer-11643) 
902 |a springer purchased ebooks 
903 |a SEB-COLL 
945 |f  - -   |g 1  |h 0  |j  - -   |k  - -   |l he   |o -  |p $0.00  |q -  |r -  |s b   |t 38  |u 0  |v 0  |w 0  |x 0  |y .i22087825  |z 02-26-20 
999 f f |i f7ce0b1b-8948-53a8-bbd9-860dd0cad7f0  |s 64d1a104-f866-51d2-ba4b-f6e870e77282 
952 f f |p Online  |a College of the Holy Cross  |b Main Campus  |c E-Resources  |d Online  |e E-Book  |h Library of Congress classification  |i Elec File  |n 1